Araştırma Makalesi
BibTex RIS Kaynak Göster

The Relationship between Fibroblast Growth Factor-23, Insulin-Like Growth Factor-1, Bone Mineral Density, Insulin Resistance, and Hyperandrogenemia in Polycystic Ovary Syndrome

Yıl 2022, Cilt: 44 Sayı: 4, 390 - 396, 31.12.2022

Enver Çiftel , Fatih Kılıçlı , Serpil Çiftel

https://doi.org/10.7197/cmj.1215068

Öz

Aims: The aim of this study was to find out the association between the Fibroblast Growth Factor-23 (FGF-23), Insulin-Like Growth Factor-1 (IGF-1), androgens, insulin resistance (IR), and bone mineral density (BMD) in patients with PCOS (Polycyctic Ovary Syndrome) and healthy controls is presented.
Materials and Methods: The FGF-23, IGF-1, and Homeostatic Model Assessment for Insulin Resistance were evaluated in 47 patients with PCOS and 26 healthy females, and BMD was evaluated only in the PCOS group. Then these parameters were compared between groups, according to the presence of IR and hyperandrogenemia.
Results: The mean FGF-23 was 137.55± 75.42 and 414.81 ± 53.02 (pg/ml), and mean IGF-1 was 28.41 ± 99.69 and 244.26 ± 58.99 (ng/ml) in patients with PCOS and healthy controls, respectively. In PCOS group, the FGF-23 was more significantly decreased in those with IR and amenorrheic. DEXA scores were found to be similar in PCOS group in terms of hyperandrogenemia and IR.
Conclusions: Our results revealed that FGF-23 levels decreased in patients with PCOS, which was particularly significant in patients with IR. According to our findings; the low level of FGF-23 in the PCOS group with IR suggests that this marker may also be associated with the complications of PCOS, but to clarify this hypothesis, this marker needs to be investigated.

Anahtar Kelimeler

Polycystic Ovary Syndrome Insulin Resistance FGF-23

Destekleyen Kurum

Unit of the Cumhuriyet University Scientific Research Projects (CUBAP)

Proje Numarası

T574 numbered project

Kaynakça

  • 1. Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J. Med Res. 2019; 150(4): 333–344.
  • 2. Ibanez L, Oberfield SE, Witchel SF,Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary N, Gambineri A, Rudaz CG, Hoeger KM, Bermejo AL, Ong K, Pena AS, Reinehr T, Santoro N, Sempere MT, Tao R, Yildiz BO, Alkhayyat H, Deeb A, Joel D, Horikawa R, Zegher F, Lee P. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm. Res. Paediatr. 2017; 88(6): 371–395
  • 3. Li Y, Chen C, Ma Y, Xiao J, Luo G, Li Y, Wu D. Multi-system reproductive metabolic disorder: Significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019;228:167–175.
  • 4. Zeng X, Xie Y-J, Liu Y-T, Long S-L, Mo Z-C. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin. Chim. Acta. 2020; 502: 214–221.
  • 5. Zhang C, Hu J, Wang W, Sun Y, Sun K. HMGB1-induced aberrant autophagy contributes to insulin resistance in granulosa cells in PCOS. FASEB J. 2020; 34(7): 9563–9574.
  • 6. Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord. 2018; 17(2):277–285.
  • 7. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003; 278 (39): 37419-26.
  • 8. Miyamoto K, Ito M, Kuwahata M, Kato S, Segawa H. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial. 2005; 9(4):331-5.
  • 9. Danziger J. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant. 2008; 23(9):2733-37.
  • 10. Lu Y, Feng JQ. FGF23 in skeletal modeling and remodeling. Curr Osteoporos Rep. 2011; 9(2):103-8.
  • 11. Martínez-García MA, Moncayo S, Insenser M, Álvarez-Blasco F, Luque-Ramírez, M, Escobar-Morreale H. F. Metabolic Cytokines at Fasting and During Macronutrient Challenges: Influence of Obesity, Female Androgen Excess and Sex. Nutrients. 2019; 11(11): 2566.
  • 12. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: Molecular mechanisms. Physiological Reviews. 2000; 80(4): 1373–1409.
  • 13. Abuduli M, Ohminami H, Otani T, Kubo H, Ueda H, Kawai Y, Masuda M, Yamanaka-Okumura H, Sakaue H, Yamamoto H, Yamamoto H, Takeda E, Taketani Y. Effects of dietary phosphate on glucose and lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 2016; 310(7): E526-38.
  • 14. Akter S, Eguchi M, Kochi T, Kabe I, Nanri A, Mizoue T. Association of Serum Calcium and Phosphate Concentrations with Glucose Metabolism Markers: The Furukawa Nutrition and Health Study. Nutrients. 2020; 12(8): 2344.
  • 15. Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB. FGF23 contributes to insulin sensitivity in obese adolescents — preliminary results. Clinical Endocrinology. 2012; 77(4): 537–40.
  • 16. Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020; 16(11) :654–667.
  • 17. Sahin SB, Ayaz T, Cure MC, Sezgin H, Ural UM, Balik G, Sahin FK. Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome. ScandJ Clin Lab Invest. 2014; 74(6): 465–469
  • 18. Yüksel O, Dökmetaş HS, Topcu S, Erselcan T, Sencan M. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab. 2001; 19(4):257-62
  • 19. Mørch NF, Aziz M, Svendsen PF. Bone mass density in lean and overweight women with polycystic ovary syndrome. ScandJ Clin Lab Invest. 2022; 82(3): 210–217
  • 20. Yang HY, Lee HS, Huang WT, Chen MJ, Chen SC, Hsu YH. Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study. J Bone Miner Metab. 2018; 36(6), 741–748.
  • 21. Zhang R, LuY, YeL, Yuan B, YuS, Qin C, Xie Y, Gao T, Drezner MK, Bonewald LF, Feng JQ. Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone miner Res. 2011; 26(5): 1047-56.
  • 22. Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N. Overexpression of fibroblast growth factor 23 suppresses osteoblast differention and matrix mineralization in vitro. J. Bone Miner Res.2008; 23(6):939·48.
  • 23. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007; 18(10): 2683-8.
  • 24. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146(11):4577-83.
  • 25. Goobel S, Lienau J, Rammoser U, Seefried L, Wintgens KF, Seufert J, Duda G, Jakob F, Ebert R. FGF23 is a putative marker for bone healing and regeneration. J Orthop Res.2009; 27(9) :1141-46.
  • 26. Westerberg PA, Tivesten Å, Karlsson MK, Mellström D, Orwoll E, Ohlsson C, Larsson TE, Linde T, Ljunggren Ö. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs) BMC Nephrol. 2013; 14:85.
  • 27. Celik E, Guzel S, Abalı R, Guzelant AY, Guzel EC, Kucukyalcin V. The relationship between fibroblast growth factor 23 and osteoporosis in postmenapousal women. Minerva Med.2013; 104(5):497-504.
  • 28. Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis. 2011; 58(5):737-45.
  • 29. Ogunmoroti O, Osibogun O, Zhao D, Mehta RC, Ouyang P, Lutsey PL, Robinson-Cohen C, Michos E D. Associations between endogenous sex hormones and FGF-23 among women and men in the Multi-Ethnic Study of Atherosclerosis. PloS one. 2022; 17(5): e0268759.

Yıl 2022, Cilt: 44 Sayı: 4, 390 - 396, 31.12.2022

Enver Çiftel , Fatih Kılıçlı , Serpil Çiftel

https://doi.org/10.7197/cmj.1215068

Öz

Proje Numarası

T574 numbered project

Kaynakça

  • 1. Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J. Med Res. 2019; 150(4): 333–344.
  • 2. Ibanez L, Oberfield SE, Witchel SF,Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary N, Gambineri A, Rudaz CG, Hoeger KM, Bermejo AL, Ong K, Pena AS, Reinehr T, Santoro N, Sempere MT, Tao R, Yildiz BO, Alkhayyat H, Deeb A, Joel D, Horikawa R, Zegher F, Lee P. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm. Res. Paediatr. 2017; 88(6): 371–395
  • 3. Li Y, Chen C, Ma Y, Xiao J, Luo G, Li Y, Wu D. Multi-system reproductive metabolic disorder: Significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019;228:167–175.
  • 4. Zeng X, Xie Y-J, Liu Y-T, Long S-L, Mo Z-C. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin. Chim. Acta. 2020; 502: 214–221.
  • 5. Zhang C, Hu J, Wang W, Sun Y, Sun K. HMGB1-induced aberrant autophagy contributes to insulin resistance in granulosa cells in PCOS. FASEB J. 2020; 34(7): 9563–9574.
  • 6. Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord. 2018; 17(2):277–285.
  • 7. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003; 278 (39): 37419-26.
  • 8. Miyamoto K, Ito M, Kuwahata M, Kato S, Segawa H. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial. 2005; 9(4):331-5.
  • 9. Danziger J. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant. 2008; 23(9):2733-37.
  • 10. Lu Y, Feng JQ. FGF23 in skeletal modeling and remodeling. Curr Osteoporos Rep. 2011; 9(2):103-8.
  • 11. Martínez-García MA, Moncayo S, Insenser M, Álvarez-Blasco F, Luque-Ramírez, M, Escobar-Morreale H. F. Metabolic Cytokines at Fasting and During Macronutrient Challenges: Influence of Obesity, Female Androgen Excess and Sex. Nutrients. 2019; 11(11): 2566.
  • 12. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: Molecular mechanisms. Physiological Reviews. 2000; 80(4): 1373–1409.
  • 13. Abuduli M, Ohminami H, Otani T, Kubo H, Ueda H, Kawai Y, Masuda M, Yamanaka-Okumura H, Sakaue H, Yamamoto H, Yamamoto H, Takeda E, Taketani Y. Effects of dietary phosphate on glucose and lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 2016; 310(7): E526-38.
  • 14. Akter S, Eguchi M, Kochi T, Kabe I, Nanri A, Mizoue T. Association of Serum Calcium and Phosphate Concentrations with Glucose Metabolism Markers: The Furukawa Nutrition and Health Study. Nutrients. 2020; 12(8): 2344.
  • 15. Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB. FGF23 contributes to insulin sensitivity in obese adolescents — preliminary results. Clinical Endocrinology. 2012; 77(4): 537–40.
  • 16. Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020; 16(11) :654–667.
  • 17. Sahin SB, Ayaz T, Cure MC, Sezgin H, Ural UM, Balik G, Sahin FK. Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome. ScandJ Clin Lab Invest. 2014; 74(6): 465–469
  • 18. Yüksel O, Dökmetaş HS, Topcu S, Erselcan T, Sencan M. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab. 2001; 19(4):257-62
  • 19. Mørch NF, Aziz M, Svendsen PF. Bone mass density in lean and overweight women with polycystic ovary syndrome. ScandJ Clin Lab Invest. 2022; 82(3): 210–217
  • 20. Yang HY, Lee HS, Huang WT, Chen MJ, Chen SC, Hsu YH. Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study. J Bone Miner Metab. 2018; 36(6), 741–748.
  • 21. Zhang R, LuY, YeL, Yuan B, YuS, Qin C, Xie Y, Gao T, Drezner MK, Bonewald LF, Feng JQ. Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone miner Res. 2011; 26(5): 1047-56.
  • 22. Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N. Overexpression of fibroblast growth factor 23 suppresses osteoblast differention and matrix mineralization in vitro. J. Bone Miner Res.2008; 23(6):939·48.
  • 23. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007; 18(10): 2683-8.
  • 24. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146(11):4577-83.
  • 25. Goobel S, Lienau J, Rammoser U, Seefried L, Wintgens KF, Seufert J, Duda G, Jakob F, Ebert R. FGF23 is a putative marker for bone healing and regeneration. J Orthop Res.2009; 27(9) :1141-46.
  • 26. Westerberg PA, Tivesten Å, Karlsson MK, Mellström D, Orwoll E, Ohlsson C, Larsson TE, Linde T, Ljunggren Ö. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs) BMC Nephrol. 2013; 14:85.
  • 27. Celik E, Guzel S, Abalı R, Guzelant AY, Guzel EC, Kucukyalcin V. The relationship between fibroblast growth factor 23 and osteoporosis in postmenapousal women. Minerva Med.2013; 104(5):497-504.
  • 28. Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis. 2011; 58(5):737-45.
  • 29. Ogunmoroti O, Osibogun O, Zhao D, Mehta RC, Ouyang P, Lutsey PL, Robinson-Cohen C, Michos E D. Associations between endogenous sex hormones and FGF-23 among women and men in the Multi-Ethnic Study of Atherosclerosis. PloS one. 2022; 17(5): e0268759.
Toplam 29 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Dahili Tıp Bilimleri Araştırma Yazıları
Yazarlar

Enver Çiftel 0000-0003-1431-5663

Fatih Kılıçlı 0000-0001-8962-7835

Serpil Çiftel 0000-0001-6962-4039

Proje Numarası T574 numbered project
Yayımlanma Tarihi 31 Aralık 2022
Kabul Tarihi 27 Aralık 2022
Yayımlandığı Sayı Yıl 2022Cilt: 44 Sayı: 4

Kaynak Göster

AMA Çiftel E, Kılıçlı F, Çiftel S. The Relationship between Fibroblast Growth Factor-23, Insulin-Like Growth Factor-1, Bone Mineral Density, Insulin Resistance, and Hyperandrogenemia in Polycystic Ovary Syndrome. CMJ. Aralık 2022;44(4):390-396. doi:10.7197/cmj.1215068